• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Xuezhikang Capsule for Type 2 Diabetes with Hyperlipemia: A Systematic Review and Meta-Analysis of Randomized Clinical Trails
【24h】

Xuezhikang Capsule for Type 2 Diabetes with Hyperlipemia: A Systematic Review and Meta-Analysis of Randomized Clinical Trails

机译：血脂康胶囊治疗高脂血症2型糖尿病的系统评价和荟萃分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective. To evaluate the efficacy and safety of Xuezhikang capsule treating type 2 diabetes with hyperlipidemia.Methods. We searched six databases to identify relevant studies published before January 2015. Two review authors independently extracted data and assessed the Cochrane risk of bias tool. We resolved disagreements with this assessment through discussion and a decision was achieved by consensus.Results. We included 21 studies (1548 participants). Treatment courses were at least 8 weeks. Overall, the risk of bias of included trials was unclear. Among them, 16 studies could conduct meta-analysis. The result showed that compared with routine group (5 studies), Xuezhikang group had more effect on decreasing TC, TG, LDL-C, and rising HDL-C. However, compared with statins group (11 studies), Xuezhikang group has less effect on decreasing TC, TG, and rising HDL-C. Meanwhile, two groups had no statistical differences of LDL-C level.Conclusion. Xuezhikang capsule may be effective for treating type 2 diabetes with hyperlipemia. Our findings should be considered cautiously due to unclear risk of bias of the included studies and low methodological quality. Therefore, more strictly designed large-scale randomized clinical trials are needed to evaluate the efficacy of Xuezhikang capsule in type 2 diabetes with hyperlipemia.
机译：目的。评价血脂康胶囊治疗高脂血症2型糖尿病的疗效和安全性。我们搜索了六个数据库，以鉴定2015年1月之前发表的相关研究。两名评论作者独立提取数据并评估Cochrane偏倚风险工具。我们通过讨论解决了对该评估的分歧，并通过共识达成了决定。我们纳入了21项研究（1548名参与者）。治疗过程至少为8周。总体而言，尚无纳入试验偏倚的风险。其中，有16项研究可以进行荟萃分析。结果表明，与常规组（5个研究）相比，血脂康组对降低TC，TG，LDL-C和升高HDL-C的影响更大。但是，与他汀类药物组（11个研究）相比，血脂康组对降低TC，TG和升高HDL-C的影响较小。同时，两组的LDL-C水平无统计学差异。血脂康胶囊可能有效治疗2型糖尿病伴高脂血症。由于不清楚所纳入研究的偏倚风险和方法学质量低下，因此应谨慎考虑我们的发现。因此，需要更严格设计的大规模随机临床试验来评估血脂康胶囊对2型糖尿病高脂血症的疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号